Miglustat Coverage for Type 1 Gaucher Disease and Niemann-Pick Disease Type C
Customize your policy alerts
Sign up for Molina Healthcare Policy C9646-A alerts
Get alerted when Policy C9646-A changes without checking for updates manually.
Monitor payer policy activity
Prior authorization and coverage criteria for oral miglustat products in adults with mild-to-moderate Type 1 Gaucher disease when enzyme replacement therapy is not a therapeutic option, and in members with Niemann-Pick disease type C with qualifying neurologic, psychiatric, or cognitive manifestations.
No material clinical or coverage changes in this revision.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.